Sumitomo Pharma (DNPUF) Stock Price, News & Analysis

Company Overview

Sumitomo Pharma Co., Ltd. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. Its activities focus primarily on central nervous system disorders, including psychiatric and neurological conditions, as well as oncology, metabolic diseases and other areas of unmet medical need.

The company’s portfolio has included medicines for schizophrenia, bipolar disorder, depression and Parkinson’s disease, along with treatments in other specialty-care categories. Sumitomo Pharma also conducts research in regenerative medicine and cell therapy, including programs intended to address serious neurological diseases.

Headquartered in Osaka, Japan, the company serves patients and healthcare providers in Japan and international markets through subsidiaries, partnerships and regional operations. Sumitomo Pharma was formed in 2005 through the merger of Dainippon Pharmaceutical and Sumitomo Pharmaceuticals and adopted its current name in 2022.

Key Stats

• Today's Range: $11.91 to $11.91
• 50-Day Range: $8.41 to $14.21
• 52-Week Range: $8.41 to $19.20
• Volume: N/A
• Average Volume: 1,303 shs
• Market Capitalization: N/A
• P/E Ratio: 0.20
• Dividend Yield: 120.63%
• Price Target: N/A
• Consensus Rating: N/A

Sumitomo Pharma Stock Analysis - MarketRank™

Sumitomo Pharma scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Sumitomo Pharma.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Sumitomo Pharma is 0.20, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.03.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sumitomo Pharma is 0.20, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 36.86.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Sumitomo Pharma has a short interest ratio ("days to cover") of 999.99, which indicates bearish sentiment.

Change versus previous month

Short interest in Sumitomo Pharma has recently decreased by 15.30%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Sumitomo Pharma pays a meaningful dividend of 1.27%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Sumitomo Pharma does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Sumitomo Pharma is 24.70%. This payout ratio is at a healthy, sustainable level, below 75%.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Sumitomo Pharma this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sumitomo Pharma insiders have not sold or bought any company stock.

Percentage Held by Institutions

7.58% of the stock of Sumitomo Pharma is held by institutions.

Company Calendar

• Today: 10/28/2026
• Next Earnings (Estimated): 10/30/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:DNPUF
• CIK: N/A
• Web: www.ds-pharma.com
• Phone: 81 6 6203 5321
• Fax: N/A
• Employees: 6,250
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 0.20
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A